Recurrent and Hodgkin’s lymphoma-associated multicentric Castleman’s disease in head and neck region

Background: Castleman’s disease (CD) is a rare lymphoproliferative disorder. It can involve single (unicentric CD) or multiple (multicentric CD) lymph nodal regions. It occurs predominantly in mediastinum, and treatment options include surgery, radiotherapy, chemotherapy, and monoclonal antibodies. Methods: Here, we describe two cases of CD which presented with stridor. The first case was a 38-year-old male, a recurrent multicentric CD in retropharyngeal and cervical lymph nodal regions, treated with radiotherapy and rituximab. The second case was a 25-year-old male, a multicentric CD in lower cervical lymph nodal region, treated with steroids and radiotherapy. He subsequently developed Hodgkin’s lymphoma and was treated for the same with chemotherapy and involved-field radiation therapy (IFRT).Results: Post-treatment, both the patients were asymptomatic and progression-free at 15 months and 42 months follow-up, respectively.Conclusions: Combined modality of treatment with radiotherapy and chemotherapy or monoclonal antibodies offers good local control in multicentric CD.

Download Full-text

Young Female Patients with Hodgkin's Lymphoma can be Safely Treated with Involved Field Radiation - New Technique to Avoid the Breasts and Decrease the Heart Dose

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2008.06.1400 ◽

2008 ◽

Vol 72 (1) ◽

pp. S473

Author(s):

B. Dabaja

Keyword(s):

Hodgkin’S Lymphoma ◽

Young Female ◽

Hodgkin's Lymphoma ◽

New Technique ◽

Female Patients ◽

Heart Dose ◽

Field Radiation ◽

Involved Field

Download Full-text

MACOP-B Regimen Followed by Involved-Field Radiation Therapy in Early-Stage Aggressive Non-Hodgkin's Lymphoma Patients: 14-Year Update Results

Leukemia & Lymphoma ◽

10.3109/10428190109097718 ◽

2001 ◽

Vol 42 (5) ◽

pp. 989-995 ◽

Cited By ~ 7

Author(s):

P. L. Zinzani ◽

V. Stefoni ◽

M. Tani ◽

E. Barbieri ◽

P. Albertini ◽

...

Keyword(s):

Radiation Therapy ◽

Hodgkin’S Lymphoma ◽

Early Stage ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Field Radiation ◽

Involved Field

Download Full-text

The Role of Radiotherapy in Hodgkin’s Lymphoma: What Has Been Achieved during the Last 50 Years?

BioMed Research International ◽

10.1155/2015/485071 ◽

2015 ◽

Vol 2015 ◽

pp. 1-8 ◽

Cited By ~ 10

Author(s):

Magdalena Witkowska ◽

Agata Majchrzak ◽

Piotr Smolewski

Keyword(s):

Radiation Therapy ◽

Safety Profile ◽

Hodgkin’S Lymphoma ◽

Antitumor Agents ◽

Standard Of Care ◽

Hodgkin's Lymphoma ◽

Field Size ◽

Field Radiation ◽

Involved Field

Currently, Hodgkin’s lymphoma (HL) has an excellent clinical outcome, with overall survival of approximately 90% in early stages of the disease. Based on young age of the majority of patients at the time of diagnosis and their long survival time, increased attention has been focused on long-term toxicity of therapy. While novel, directly targeting antitumor agents, with an excellent safety profile, have been developed for HL treatment, the role of radiotherapy is still debated. Radiotherapy may induce cardiovascular disease and impairment of thyroid or pulmonary function and, most importantly, may lead to development of secondary cancers. As a consequence, the current radiation therapy planning paradigm is mainly focused on a reduction of field size. As it was investigated in clinical trials regional therapy is as effective as extended field radiotherapy, but less toxic. Although chemotherapy is the mainstay of HL treatment, consolidative involved field radiation therapy is still considered to be the standard of care in both early and advanced stages. Recently, further field reduction has been investigated to further decrease the late radiation-induced toxicity. In this paper we describe the role and safety profile of radiotherapy in the past and present and hope for the novel techniques in the future.

Download Full-text

What is the role of involved field radiation among children with localized Non-Hodgkin's lymphoma?

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(86)90633-4 ◽

1986 ◽

Vol 12 ◽

pp. 159

Author(s):

Sarah S. Donaldson ◽

Michael P. Link ◽

Jonathan J. Shuster ◽

Costan Berard ◽

Sharon B. Murphy

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Field Radiation ◽

Involved Field

Download Full-text

Coexistence of Hodgkin’s Lymphoma and Castleman’s Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy

Case Reports in Oncological Medicine ◽

10.1155/2013/487205 ◽

2013 ◽

Vol 2013 ◽

pp. 1-4 ◽

Cited By ~ 1

Author(s):

Amina Mohtaram ◽

Mohammed Afif ◽

Tanae Sghiri ◽

Amal Rami ◽

Rachida Latib ◽

...

Keyword(s):

Lymph Node ◽

Hodgkin's Disease ◽

Cervical Lymph Node ◽

Hodgkin’S Lymphoma ◽

Hodgkin’S Disease ◽

Castleman’S Disease ◽

Hodgkin's Lymphoma ◽

Castleman's Disease ◽

Cervical Lymph Nodes ◽

Response To Chemotherapy

Background. Castleman’s disease is a rare clinicopathological entity of unknown origin. Coexistence of Hodgkin’s lymphoma and Castleman’s disease is rare. We report a case of Hodgkin’s disease of cervical lymph nodes in a patient previously diagnosed with Castleman’s disease.Case Presentation. A 43-year-old man admitted in July 2009 for a right cervical pain with lymph node at the physician examination. He underwent a right adenectomy and histological studies showed typical features of Castleman’s disease. Three years after, the patient consulted for increasing the volume of cervical lymph node. Clinical examination showed a right cervical lymph node of 3 cm. The computed tomography scan of chest, abdominal and pelvic was normal. Histological and immunohistochemical studies of cervical lymph node biopsy specimen were in favor of Castleman’s disease associated with Hodgkin’s disease. Reed-Sternberg cells were positive for CD15 and CD30. The patient received chemotherapy based on anthracyclines, bleomycin, vinblastine, and dacarbazine (ABVD) and radiotherapy with complete response.Conclusion. Prevalence of Hodgkin’s lymphoma in Castleman’s disease is more difficult to establish because of the low number of cases reported in the literature.

Download Full-text